Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03322566
Title A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Incyte Corporation
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Paclitaxel + Pembrolizumab

Epacadostat + Pembrolizumab

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Pemetrexed Disodium

Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab

Cisplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries USA | ITA | ESP | CAN

Additional content available in CKB BOOST